INCYTE Executive and Leadership Team

Bill Meury, the Chief Executive Officer at INCYTE, directs the overarching strategic vision for the biopharmaceutical organization. Overseeing the commercialization of JAKAFI and Iclusig, the Chief Executive Officer ensures that therapeutic development aligns with the urgent needs of patients suffering from myelofibrosis and leukemia. This leadership role involves constant engagement with the Board to drive long-term value and market expansion across the United States. By prioritizing innovation in kinase inhibitor research, Bill Meury maintains the competitive edge of the company within the complex pharmaceutical landscape. The Chief Executive Officer manages the integration of research outcomes into scalable market strategies, ensuring that clinical successes translate into tangible patient benefits. Through disciplined resource allocation and a focus on high-impact oncology solutions, the Chief Executive Officer secures the future growth trajectory of the firm while upholding the highest standards of scientific integrity and operational excellence.

Suky Upadhyay, the Executive Vice President & Chief Financial Officer at INCYTE, manages the fiscal health and capital allocation strategies of the organization. Overseeing financial planning and analysis, the Chief Financial Officer ensures that the company maintains the liquidity required to fund intensive research and development cycles for oncology therapeutics. This leadership role involves rigorous oversight of the commercial performance of JAKAFI and Iclusig, providing the financial transparency necessary for investor confidence. Suky Upadhyay directs the budgeting processes that support the expansion of the clinical pipeline, balancing immediate operational needs with long-term growth objectives. By optimizing the capital structure and managing financial risks, the Chief Financial Officer enables the firm to pursue strategic acquisitions and internal innovation. The Chief Financial Officer works closely with the Board to communicate financial performance and strategic direction, ensuring that every dollar invested contributes to the mission of improving patient outcomes in the oncology sector.

Suketu Upadhyay, the Chief Financial Officer & Executive VP at INCYTE, oversees the enterprise-wide financial governance and reporting standards. Managing the treasury and tax functions, the Chief Financial Officer & Executive VP ensures compliance with regulatory requirements while maximizing shareholder value. This role involves evaluating the economic viability of new drug development projects and assessing the market potential for existing kinase inhibitors. Suketu Upadhyay drives the financial strategy that supports the company's presence in the United States pharmaceutical market. By implementing sophisticated forecasting models, the Chief Financial Officer & Executive VP provides the insights needed to navigate the volatile biopharmaceutical landscape. The Chief Financial Officer & Executive VP collaborates with the commercial teams to refine pricing strategies and revenue projections, ensuring that the company remains financially robust. Through disciplined fiscal management, the Chief Financial Officer & Executive VP secures the resources necessary to sustain the company's commitment to oncology research and patient care.

Pablo Cagnoni, the President, Global Head of Research & Development at INCYTE, directs the discovery and early-stage development of the company's innovative oncology portfolio. Overseeing the global research laboratories, the President, Global Head of Research & Development identifies novel kinase inhibitors and therapeutic targets that address unmet medical needs. This leadership role involves fostering a culture of scientific excellence and collaboration across international research sites. Pablo Cagnoni manages the pipeline of experimental drugs, ensuring that the most viable candidates advance to clinical testing. By integrating cutting-edge science with strategic business goals, the President, Global Head of Research & Development drives the long-term innovation engine of the firm. The President, Global Head of Research & Development works closely with the clinical development teams to ensure a seamless transition from laboratory discovery to human trials, ultimately expanding the company's impact on the treatment of complex cancers and hematologic conditions.

Jennifer Liu, the Chief of Staff at INCYTE, coordinates cross-functional initiatives to streamline executive decision-making processes. Managing the flow of information between the C-suite and various departments, the Chief of Staff ensures that strategic priorities receive immediate attention and resources. This role involves facilitating alignment on corporate objectives, particularly regarding the development of therapeutics for polycythemia vera and other oncology indications. Jennifer Liu optimizes internal communication channels to enhance organizational agility and responsiveness to market shifts. By overseeing the execution of high-level projects, the Chief of Staff supports the broader mission of delivering life-saving treatments to patients. The Chief of Staff acts as a central point of contact for complex operational challenges, driving efficiency across the enterprise. Through meticulous planning and stakeholder management, the Chief of Staff enables the leadership team to focus on core biopharmaceutical advancements while maintaining a cohesive and productive corporate environment.

Soni Basi, the Executive Vice President & Chief Human Resources Officer at INCYTE, architects the talent strategy necessary to support a high-growth biopharmaceutical environment. Overseeing global workforce development, the Chief Human Resources Officer ensures that the company attracts and retains top-tier scientific and commercial talent. This leadership role involves fostering a culture of innovation that directly supports the discovery of new kinase inhibitors. Soni Basi designs comprehensive programs for employee engagement and professional growth, aligning human capital with the specific demands of the oncology market. By managing organizational design and performance management systems, the Chief Human Resources Officer drives the operational efficiency required to bring complex therapeutics to patients. The Chief Human Resources Officer collaborates with other executives to ensure that the organizational structure remains agile and capable of scaling with the company's expanding portfolio of cancer treatments, ultimately strengthening the internal foundation for long-term success.

Andrew Blyton, the Vice President & Chief Information Officer at INCYTE, directs the digital infrastructure and data security frameworks essential for modern drug discovery. Overseeing the integration of advanced analytics into the research and development pipeline, the Chief Information Officer ensures that scientific teams possess the computational power to analyze complex clinical data. This role involves protecting intellectual property and patient information through robust cybersecurity measures across all North American operations. Andrew Blyton manages the technological roadmap to support the commercialization of JAKAFI and other key therapeutics. By implementing scalable cloud solutions and data management systems, the Chief Information Officer enhances the speed and accuracy of clinical trials. The Chief Information Officer collaborates with the research teams to leverage digital tools for identifying new therapeutic targets, ensuring that the company remains at the forefront of biopharmaceutical innovation through superior technological capabilities and data-driven decision-making processes.

Steven Stein, the Executive VP, Chief Medical Officer & Head of Late-stage Development at INCYTE, leads the clinical evaluation and regulatory approval processes for the company's therapeutic pipeline. Overseeing late-stage clinical trials, the Chief Medical Officer & Head of Late-stage Development ensures that all drug candidates meet the highest safety and efficacy standards before reaching the market. This leadership role involves managing interactions with health authorities to facilitate the approval of treatments for myelofibrosis and other cancers. Steven Stein directs the medical strategy that guides the transition of compounds from research to commercial availability. By supervising the clinical development teams, the Chief Medical Officer & Head of Late-stage Development ensures that data integrity remains the cornerstone of the company's regulatory submissions. The Chief Medical Officer & Head of Late-stage Development collaborates with research leaders to prioritize the most promising candidates, directly impacting the speed at which life-saving therapies reach patients in need.